Delivery Order SPE2DB24D1021-SPE2DB25FFBAC
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,938.30 to AmerisourceBergen Drug Corp for the supply of Trulicity 1.5 mg/0.5 mL pen injectors on July 14, 2025, with completion targeted for July 15, 2025. This firm fixed-price delivery order represents a non-competitive, non-set-aside procurement executed through DLA's broader pharmaceutical supply chain. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate...
- The Defense Logistics Agency awarded a $5,555.55 delivery order to AmerisourceBergen Drug Corp for Trulicity 1.5 mg/0.5 ml pen injectors on September 17, 2025, with an ultimate completion date of September 18, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The work will be performed...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,194.83 to AmerisourceBergen Drug Corp for the supply of Trulicity 1.5 mg/0.5 ml pen injectors. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by May 21, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location and deliver this diabetes medication as part of federal medical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,678.64 for Trulicity 1.5 mg/0.5 ml pen injectors on June 27, 2025, with completion expected by June 30, 2025. This is a firm fixed-price, non-set-aside competitive award to be performed at the contractor's Conshohocken, Pennsylvania location. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,351.35 to AmerisourceBergen Drug Corp for the supply of Trulicity 4.5 mg/0.5 ml pen injectors on July 18, 2025. This firm fixed-price delivery order, with an ultimate completion date of July 21, 2025, represents a competitively awarded contract with no set-aside designation. The products will be delivered to Conshohocken, Pennsylvania, the location of AmerisourceBergen's corporate headquarters and primary operations center....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Trulicity 4.5 mg/0.5 ml pen injectors with a firm fixed price ceiling value of $2,644.53 and an ultimate completion date of July 22, 2025. This is a non-set-aside competitive award executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion prime vehicle running through December 2026 that supports global...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,716.43 to AmerisourceBergen Drug Corp for the supply of Trulicity 1.5 mg/0.5 ml pen injectors on August 19, 2025, with completion scheduled for August 20, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under a larger contract vehicle...
- The Defense Logistics Agency awarded a delivery order valued at $5,050.63 to AmerisourceBergen Drug Corp for the supply of Trulicity 1.5 mg/0.5 mL pen injectors on August 18, 2025, with completion targeted for August 19, 2025. The contract employs firm fixed pricing under a non-competitive delivery order structure and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Trulicity 1.5 mg/0.5 ml pen injectors valued at $1,435.89. This is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and represents a non-set-aside competitive award. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,801.80 to AmerisourceBergen Drug Corp for the supply of Trulicity 1.5 mg/0.5 ml pen injectors on May 12, 2025. This is a firm fixed price, non-set-aside contract with a completion date of May 13, 2025, and performance will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract represents a single delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FFBACDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,501.50 to AmerisourceBergen Drug Corp for the supply of Trulicity 1.5 mg/0.5 mL pen injectors on a firm fixed-price basis. The award, issued on September 22, 2025, represents a non-competitive delivery against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. This diabetes medication will be delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of September 23, 2025. This delivery order is issued under AmerisourceBergen's larger $999,999,999.00 Pharmaceutical Prime Vendor Global Program IDC (designated SPE2DX) with DLA, which runs through December 2026 and serves as the primary vehicle for supplying pharmaceuticals and medical supplies to military healthcare systems worldwide. As a major pharmaceutical distributor, AmerisourceBergen maintains a comprehensive portfolio of federal contracts with DLA covering diverse therapeutic areas including diabetes treatments, neurological medications, pain management products, and specialized medical supplies. The company's selection demonstrates its established capability to meet federal procurement requirements and support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 9/22/25 |